WASHINGTON — Independent advisers to the Food and Drug Administration voted 6-0 Friday that a large Phase 3 trial of Leqembi verifies a clinical benefit for people with early Alzheimer’s disease, a decisive recommendation that strengthens Eisai and Biogen’s case for converting the drug’s accelerated approval into a traditional approval. The FDA is not required to follow advisory-committee recommendations, and a final agency decision remains pending, but the unanimous vote marks an important step for a therapy intended not simply to treat symptoms but to slow underlying disease progression.

The FDA’s June 9 meeting record says the Peripheral and Central Nervous System Drugs Advisory Committee was asked to evaluate whether the confirmatory BAN2401-G000-301 study, better known as Clarity AD, verified the clinical benefit required after Leqembi received accelerated approval in January. The supplemental application covers patients with mild cognitive impairment or mild dementia due to Alzheimer’s disease, the population studied in the trial.

A 1,795-patient trial shows statistically significant slowing

Clarity AD enrolled 1,795 participants with early Alzheimer’s disease and evidence of brain amyloid. Results published in the New England Journal of Medicine showed that patients receiving lecanemab every two weeks declined more slowly over 18 months than those receiving placebo on the Clinical Dementia Rating–Sum of Boxes scale, the trial’s primary endpoint. The adjusted mean change was 1.21 points with lecanemab and 1.66 with placebo, a difference of 0.45 points, corresponding to about 27% less decline.

Eisai and Biogen said in their June 9 statement that all six voting members agreed the study verified clinical benefit. The companies also emphasized statistically significant effects on the trial’s secondary measures of cognition and daily function. The magnitude of benefit remains a subject of clinical debate: Leqembi does not restore lost memory or reverse established dementia, but the trial indicates that it can slow the pace of worsening in appropriately selected patients.

The drug already has accelerated approval, but on a different evidentiary basis

FDA granted Leqembi accelerated approval on January 6 based on its ability to reduce amyloid plaques in the brain, a surrogate endpoint considered reasonably likely to predict clinical benefit. The agency’s January approval letter required a confirmatory study to verify and describe that benefit. Friday’s committee meeting was therefore not a first review of the drug; it was an assessment of whether the larger clinical-outcomes trial satisfied the condition attached to accelerated approval.

The FDA’s Drug Trials Snapshot from the accelerated approval describes the indicated population as patients in the mild cognitive impairment or mild dementia stage with confirmed amyloid pathology. Leqembi is a monoclonal antibody directed against aggregated forms of amyloid beta and is administered by intravenous infusion every two weeks.

Safety remains the central counterweight to the efficacy signal

The same trial that established slower decline also documented important adverse effects. Eisai reported amyloid-related imaging abnormalities with edema or effusion, known as ARIA-E, in 12.6% of Leqembi recipients compared with 1.7% receiving placebo. ARIA-H, which includes microhemorrhages, macrohemorrhages and superficial siderosis, occurred in 17.3% of Leqembi patients and 9.0% of placebo patients. Infusion reactions occurred in 26.4% of treated patients.

ARIA is frequently asymptomatic and detected on magnetic-resonance imaging, but it can cause headache, confusion, visual symptoms and other neurologic problems and can rarely become serious or life-threatening. The Washington Post’s June 9 account of the advisory meeting noted that panelists spent significant time discussing patients with cerebral amyloid angiopathy, people taking anticoagulants and other groups that may face higher bleeding risk. The committee did not conclude that those uncertainties erased the trial’s benefit, but they are likely to shape labeling, monitoring and clinical selection if traditional approval is granted.

Medicare coverage could determine whether approval translates into access

Regulatory status is only one part of Leqembi’s practical future because most patients with Alzheimer’s disease are old enough to rely on Medicare. On June 1, the Centers for Medicare & Medicaid Services announced a coverage framework under which anti-amyloid drugs that receive traditional FDA approval would be covered in appropriate settings when clinicians participate in collection of real-world information through a registry.

That approach is broader than the limited Medicare coverage applied to drugs in this class while they remain under accelerated approval, but it still creates an evidence-generation requirement. Access will therefore depend on more than a prescription: patients need confirmation of amyloid pathology, clinicians capable of administering twice-monthly infusions, MRI monitoring for ARIA and practices willing to satisfy Medicare’s coverage conditions. Leqembi’s list price is $26,500 a year before infusion, imaging and related care costs, adding another layer to the access debate.

The next decision belongs to FDA

The advisory committee’s role is to provide expert scientific advice, not to approve the drug itself. FDA’s meeting materials make clear that the agency must now decide whether Clarity AD fulfills the post-marketing requirement and supports traditional approval. Eisai says the application has priority review with an agency action date of July 6.

For patients and families, the 6-0 vote represents evidence that an anti-amyloid therapy can produce a measurable change in the clinical course of early Alzheimer’s disease, not merely reduce plaque on a brain scan. The benefit is modest, treatment is intensive and important safety questions remain. Yet the committee’s conclusion establishes that the central regulatory question has shifted: the debate is no longer whether Leqembi affects a biomarker, but how much its demonstrated slowing of decline is worth when weighed against ARIA, infusion burdens, cost and the infrastructure required to deliver it safely.